1. Deal Structure and Pharmacy Valuation: the Foundation of Every Transaction
The two most fundamental decisions are deal structure and pharmacy valuation, as these shape liability allocation, tax treatment, and the regulatory approvals required before closing.
What Is the Difference between an Asset Purchase and a Stock Purchase in a Pharmacy Deal?
In an asset purchase the buyer selects the specific assets and liabilities it acquires, leaving behind unwanted obligations, making it the preferred structure for most pharmacy buyers because it provides the cleanest title and most limited liability. In a stock purchase the buyer acquires the entire entity including all liabilities, which benefits the seller from a tax perspective but exposes the buyer to every contingent liability the entity carries.
Asset purchase agreement and deal structuring counsel can advise on the relative advantages of each structure, assess the tax and liability implications, and develop the deal structure strategy.
| Factor | Asset Purchase | Stock Purchase |
|---|---|---|
| What transfers | Specific assets and liabilities selected by buyer | All assets and liabilities of the entire legal entity |
| Liability exposure | Buyer generally not liable for pre-closing liabilities | Buyer assumes all existing and contingent liabilities |
| DEA registration | Buyer must obtain a new DEA registration before closing | Existing DEA registration remains with the entity |
| State pharmacy license | New license application required in most states | Existing license may transfer with change of ownership filing |
| Tax treatment | Generally more favorable for buyer (step-up in asset basis) | Generally more favorable for seller |
| Preferred by | Buyers (clean title, limited liability) | Sellers (simpler; lower tax burden on gain) |
Business acquisition transactions and corporate acquisition counsel can advise on how the deal structure affects the transaction timeline and post-closing obligations.
How Is an Independent Pharmacy Valued before a Sale?
An independent pharmacy is typically valued using a multiple of adjusted EBITDA combined with a prescription file value reflecting the recurring revenue stream measured by scripts per day and average reimbursement per script. Physical inventory is valued at cost and added to the purchase price at closing based on an independent count conducted one to three days before closing.
Business sale transactions and corporate advisory counsel can advise on the pharmacy valuation methodology, assess whether the proposed price reflects true value, and develop the valuation and negotiation strategy.
2. Due Diligence: What Every Buyer Must Investigate before Making an Offer
Due diligence in a pharmacy acquisition covers pharmacy-specific legal, financial, regulatory, and operational matters that general corporate counsel may not identify without healthcare sector experience.
What Does Due Diligence Cover in a Pharmacy Acquisition?
Due diligence covers three years of financial records, all DEA and state pharmacy licenses and regulatory action history, the complete set of PBM contracts and their assignability, prescription file data, the real property lease, employment agreements, pending litigation, and controlled substance reconciliation records. A buyer who skips due diligence frequently discovers post-closing that a PBM contract is non-assignable, a lease cannot be transferred, or a regulatory action has affected reimbursement rates.
Sale of business and business transfer counsel can advise on the due diligence scope, assess key risks, and develop the due diligence plan and risk allocation strategy.
What Pbm Contract and Reimbursement Issues Must a Buyer Examine before Closing?
Most PBM contracts allow the PBM to terminate or renegotiate reimbursement rates upon a change of ownership, and a buyer who closes without written consent to assignment or without verifying the new owner qualifies for each network can find itself unable to fill prescriptions for the majority of its patients. PBM contract review should begin early in due diligence so any qualification issues can be resolved before the transaction is announced.
Pharmacy reimbursement and healthcare compliance and regulatory counsel can advise on PBM contract transferability, assess the impact on deal value, and develop the PBM contract review and transition strategy.
3. Regulatory Approvals, License Transfers, and Antitrust Considerations
A pharmacy transaction requires regulatory approvals and license transfers with no equivalent in most other business acquisitions, and the sequence of these steps determines whether the pharmacy stays open continuously through the change of ownership.
What Regulatory Approvals and License Transfers Are Required When a Pharmacy Changes Hands?
A pharmacy change of ownership requires new or transferred licenses from the state board of pharmacy, a new DEA registration or transfer depending on deal structure, a new state controlled substances registration where required, and in some states Medicaid agency approval before the new owner can bill. These approvals must be sequenced so the pharmacy's licenses remain active in the new owner's name from the moment of transfer.
Pharmacy formation and pharmacy management counsel can advise on state board and DEA change of ownership requirements, assess the regulatory timeline, and develop the licensing and transition strategy.
What Antitrust Considerations Apply to a Pharmacy Merger or Acquisition?
Most pharmacy acquisitions fall below the HSR threshold and do not require mandatory pre-merger notification, but larger transactions involving regional chains or specialty pharmacy platforms can attract FTC scrutiny. A buyer whose transaction approaches the HSR threshold should consult antitrust counsel early to assess whether a filing is required and whether the deal presents market concentration issues.
Antitrust and competition and antitrust practice counsel can advise on FTC merger review standards, assess whether the deal triggers an HSR notification obligation, and develop the antitrust clearance strategy.
4. Closing the Deal and Managing Post-Closing Obligations
Closing a pharmacy transaction requires confirming every required license and contract has been transitioned before the buyer assumes operational control, and the seller's obligations under the purchase agreement continue post-closing.
What Happens at the Closing of a Pharmacy Acquisition?
At closing the parties execute the purchase agreement, bill of sale, and assignment and assumption agreements, the buyer delivers the purchase price and escrow amounts, and the seller delivers possession of all assets, keys, and the executed lease assignment. In a well-managed transaction all required licenses and PBM contracts will have been confirmed before closing so the pharmacy continues operating without interruption.
Corporate law and asset purchase transactions counsel can advise on closing documentation and escrow arrangements, assess whether all approvals have been obtained, and develop the closing execution strategy.
What Post-Closing Obligations Does a Pharmacy Buyer Typically Face?
After closing the buyer must complete a final inventory reconciliation, finish remaining license notifications, transition operating systems and billing credentials, and provide patients with required ownership change notices. The seller remains bound by indemnification obligations for the survival period, typically twelve to thirty-six months, and by non-compete covenants restricting the seller from opening a competing pharmacy within a defined geographic area and time period.
Healthcare practice management and corporate compliance and risk management counsel can advise on post-closing integration obligations, assess whether all licenses and contracts have been transitioned, and develop the post-closing compliance strategy.
27 Mar, 2026
